戻る Agenda
Session 5: Risk Minimisation Measures
Session Chair(s)
Raghda Mohamed
Patient Safety & Pharmacovigilance Cluster Lead - West Gulf, East Gulf and Leva
Takeda, United Arab Emirates
The primary goal of a Risk Minimization Plan (RMiP) is to develop activities that help patients and health care providers understand an important known or potential risk associated with a drug and to lessen the chance that a serious side effect might occur. This session will share good practices across MENA region and present examples from EU-RMP creation.
Speaker(s)
Risk Minimization Activities
Raghda Mohamed
Takeda, United Arab Emirates
Patient Safety & Pharmacovigilance Cluster Lead - West Gulf, East Gulf and Leva
Challenges and good practices from other regions
Hadir Rostom
Pharmaceutical Affairs Central Administration (CAPA), Ministry of Health, Egypt, Egypt
Head, Egyptian Pharmaceutical Vigilance Center (EPVC)
Risk Minimisation Plan in EU
Mohamed Abdillahi
Pfizer, United Kingdom
Risk Management Product Lead